Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucos...
Main Authors: | Uwe K. Zettl, Paulus Rommer, Petra Hipp, Robert Patejdl |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285615612659 |
Similar Items
-
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
by: Alessandro Enrico Grimaldi, et al.
Published: (2019-01-01) -
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
by: Peter Flachenecker, et al.
Published: (2018-07-01) -
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
by: Überall MA
Published: (2020-02-01) -
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray
by: Etges T, et al.
Published: (2016-11-01) -
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
by: Marie D’hooghe, et al.
Published: (2021-06-01)